Related Experiment Video
Updated: Jul 31, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
Characterization of the C6D7-RBD Human Monoclonal Antibody Specific to the SARS-CoV-2 S Protein Receptor-Binding
Ya O Romanenko1, M V Silkina1, A S Kartseva1
1Federal Budget Institution of Science State Research Center for Applied Microbiology and Biotechnology, Obolensk, Moscow region, 142279 Russian Federation.
Abstract:
The new coronavirus infection COVID-19 is an acute viral disease that affects primarily the upper respiratory tract. The etiological agent of COVID-19 is the SARS-CoV-2 RNA virus (Coronaviridae family, Betacoronavirus genus, Sarbecovirus subgenus). We have developed a high-affinity human monoclonal antibody, called C6D7-RBD, which is specific to the S protein receptor-binding domain (RBD) from the SARS-CoV-2 Wuhan-Hu-1 strain and exhibits virus-neutralizing activity in a test with recombinant antigens: angiotensin-converting enzyme 2 (ACE2) and RBD.

